Pfenex Moves Forward with Lucentis Biosimilar (OIS@ASRS 2016) скачать в хорошем качестве

Pfenex Moves Forward with Lucentis Biosimilar (OIS@ASRS 2016)

PAYING FOR BREAKTHROUGH EYE THERAPIES (BIOLOGICS, BIOSIMILARS & GENE THERAPIES) (Company Presentations - Pfenex) panel from Healthegy's OIS@ASRS 2016: Moderated by: Tarek Hassan, MD Presenter: Hubert Chen, Chief Medical Officer - Pfenex For more on Ophthalmology Innovation News & Events visit: http://ois.net/ The lead-up to OIS@ASRS had been eventful for biotech company PFEnex, as Hubert C. Chin, MD, chief medical officer, reported to the “Paying for Breakthrough Eye Therapies” session. Top-line results of the completed Phase I/II trial of the company’s lead candidate, PF582, a Lucentis biosimilar, showed similar safety and efficacy to the index agent, and PFEnex regained full rights to PF582 from former partner Pfizer. “Combined with the approaching Phase I/II study results, along with what we believe to be a readiness for manufacturing tech transfer, we are very excited in terms of exploring all strategic options in terms of what to do with PF582 as it returns back to us,” Dr. Chin said. Those options include exploring new partnerships since Pfizer ended its development arrangement with PFEnex to develop PF582, which Dr. Chin announced at OIS@ASRS. Read more about this panel here: http://ois.net/pfenex-moves-forward-w...